May 11, 2018 | In a letter to Novartis, U.S. Sen. Ron Wyden (D-Ore.) suggested the payments may have been linked to a groundbreaking Novartis cancer treatment that was being reviewed last year by the FDA. And he also noted the drug maker was holding talks last year with the CMS about a unique reimbursement deal for the medication. STAT